0001193125-20-174060.txt : 20200619 0001193125-20-174060.hdr.sgml : 20200619 20200619163059 ACCESSION NUMBER: 0001193125-20-174060 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200617 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20200619 DATE AS OF CHANGE: 20200619 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001662524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472608175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38137 FILM NUMBER: 20976014 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-207-0202 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 8-K 1 d941975d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2020

 

 

Akcea Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-38137   47-2608175

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

22 Boston Wharf Road

9th Floor

Boston, MA

     02210
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 207-0202

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange on which registered

Common stock   AKCA   NASDAQ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of Chief Medical Officer

On June 17, 2020, Louis St. L. O’Dea, Chief Medical Officer of Akcea Therapeutics, Inc. (the “Company”) notified the Company that he plans to retire and therefore will resign his position as Chief Medical Officer of the Company. Dr. O’Dea’s resignation will be effective July 7, 2020.

In accordance with the retention agreement dated March 16, 2020 (the “Retention Agreement”) entered between Dr. O’Dea and the Company, Dr. O’Dea will be entitled to receive medical benefit continuation, a lump sum severance payment equal to 12 months of his then-current base salary, and an amount equal to 50% of his target annual cash performance bonus for 2020.

In addition, in accordance with the Retention Agreement, following his departure from the Company, Dr. O’Dea has agreed to provide consulting services to the Company to support ongoing development and regulatory initiatives and to assist with the transition of his responsibilities as Chief Medical Officer to his successor for up to six months.

The foregoing description of the Retention Agreement does not purport to be complete and is qualified in its entirety by the full text of such document, which was filed as an exhibit to the Current Report on Form 8-K filed on March 20, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

AKCEA THERAPEUTICS, INC.

Date: June 19, 2020     By:   /s/ Joshua F. Patterson
     

     Joshua F. Patterson

     

     General Counsel